Skip to content
PsilodexMedication × psilocybin
Your list 00
Other substances
Brand names
—
Reviewed 2026-10-02

GHB / GBL / 1,4-butanediol

Clinical contraindication
Relative
Substantial clinical concern; the literature treats it as a reason for caution or deferral.
Best available evidence
Case reports
Half-life
Not recorded
Named in state rules?
CONot named
ORNot named
NMPending
Cite asPsilodex: ghb-gbl · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

CR

CNS depressant: high doses slow breathing and heart rate, and effects stack with other sedatives. Regular use can produce dependence, and withdrawal can be severe, with delirium in some admissions. Distinct from prescribed sodium oxybate.

Human data with psilocybin
Case reports or surveys only
Evidence types on this record
CRCase reports or online surveys

02 Pharmacology relevant to psilocybin

2 listed · counted on reports
Sedating or CNS depressant
Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Withdrawal or rebound if stopped abruptly
Stopping suddenly can cause withdrawal or a rebound of symptoms. Any change to the dose is the prescriber’s decision. Sources [2]

03 State rules

Official text governs
CO4 CCR 755-1
Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30
OROAR 333-333
Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30
NM7.35.3 NMAC (proposed)
Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

2
  1. US Drug Enforcement Administration. Drug Fact Sheets (per-entry link). — greatly slowed breathing and heart rate; GBL/1,4-BD analogues
  2. Siefried KJ, Freeman G, Roberts DM, et al. Inpatient GHB withdrawal management in an inner-city hospital in Sydney, Australia: a retrospective medical record review. Psychopharmacology (Berl) 2023;240(1):127–135. — inpatient GHB withdrawal; delirium in 16% of admissions

Report an error in this record →

Before you startTerms v2026-10-01

What Psilodex is, and isn't.

  1. 01It describes published evidence and state rules. It is not medical advice, a screening decision, or clearance to participate.
  2. 02Starting, stopping, or changing a medication is the prescriber's decision. Bring the report to them.
  3. 03Your list stays in this browser. Nothing you enter is sent anywhere.

In an emergency, call 911. Full terms and privacy.